Vimal Mehta - Jun 25, 2021 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Signature
/s/ Vimal Mehta
Stock symbol
BTAI
Transactions as of
Jun 25, 2021
Transactions value $
-$14,589,493
Form type
4
Date filed
6/29/2021, 05:23 PM
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Sale -$14.6M -473K -5.25% $30.83 8.55M Jun 25, 2021 See footnotes F1, F2
holding BTAI Common Stock 2K Jun 25, 2021 By Spouse
holding BTAI Common Stock 9.96K Jun 25, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.
F2 These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.